Screener
Axsome Therapeutics AXSM Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's operating lease liabilities (total)?
- Axsome Therapeutics (AXSM) reported operating lease liabilities (total) of $23.01M in Q1 2026.
- How has Axsome Therapeutics's operating lease liabilities (total) changed year-over-year?
- Axsome Therapeutics's operating lease liabilities (total) decreased by 5.5% year-over-year, from $24.36M to $23.01M.
- What is the long-term trend for Axsome Therapeutics's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Axsome Therapeutics's operating lease liabilities (total) has grown at a 67.3% compound annual growth rate (CAGR), from $1.8M to $23.62M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.
Ask your AI about Axsome Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude